Compare · FRNM vs XGN
FRNM vs XGN
Side-by-side comparison of Freenome Inc. (FRNM) and Exagen Inc. (XGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FRNM and XGN operate in Medical Specialities (Health Care), so they compete in similar markets.
- FRNM is the larger of the two at $1.04B, about 11.3x XGN ($92.1M).
- XGN has been more active in the news (14 items in the past 4 weeks vs 6 for FRNM).
- XGN has more recent analyst coverage (8 ratings vs 0 for FRNM).
- Company
- Freenome Inc.
- Exagen Inc.
- Price
- -
- -
- Market cap
- $1.04B
- $92.1M
- 1M return
- -
- -51.47%
- 1Y return
- -
- -52.11%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 6
- 14
- Recent ratings
- 0
- 8
Freenome Inc.
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's development of SimpleScreen CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional indications is designed to increase cancer detection among millions of at-risk individuals.
Exagen Inc.
Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with rapid and reliable results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute and the AHN Autoimmunity Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Latest FRNM
- Freenome to Participate in the Piper Sandler 38th Annual Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Freenome Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Freenome Inc.
- SEC Form 10-Q filed by Freenome Inc.
- Freenome Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Freenome Reports Third Quarter 2026 Financial Results
Latest XGN
- SEC Form EFFECT filed by Exagen Inc.
- SEC Form 424B5 filed by Exagen Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Exagen Inc.
- Large owner Chernett Jorey sold $745,795 worth of shares (167,504 units at $4.45), decreasing direct ownership by 6% to 2,529,436 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Exagen Inc.
- Large owner Chernett Jorey bought $372,977 worth of shares (71,315 units at $5.23), increasing direct ownership by 3% to 2,696,940 units (SEC Form 4)
- Large owner Chernett Jorey sold $69,167 worth of shares (11,265 units at $6.14) and bought $91,242 worth of shares (15,585 units at $5.85), increasing direct ownership by 0.16% to 2,625,625 units (SEC Form 4)
- SEC Form S-3 filed by Exagen Inc.
- SEC Form 10-Q filed by Exagen Inc.
- Exagen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits